U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C3H8O3S3
Molecular Weight 188.289
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 2,3-DIMERCAPTO-1-PROPANESULFONIC ACID

SMILES

OS(=O)(=O)CC(S)CS

InChI

InChIKey=JLVSRWOIZZXQAD-UHFFFAOYSA-N
InChI=1S/C3H8O3S3/c4-9(5,6)2-3(8)1-7/h3,7-8H,1-2H2,(H,4,5,6)

HIDE SMILES / InChI

Molecular Formula C3H8O3S3
Molecular Weight 188.289
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Unithiol was developed in the Soviet Union in the late 1950s. It only became more widely used in America and Western Europe since the mid-1970s, and particularly since the late 1970s when the Heyl Company in Germany began production. It remained the mainstay of chelation treatment of arsenic and mercury intoxication for more than half a century. Unithiol has been used in the management of acute and chronic poisoning with a number of different metals and metalloids, and is particularly useful for arsenic, bismuth and mercury. Unithiol can be given parenterally or orally depending on the clinical situation and severity of poisoning. Its action mechanism is close that of complexones. Active sulfhydryl groups enter into reactions with thiol poisons present in blood and tissues, form not toxic complex with them eliminated with urine. The poisons fixation results in the body enzyme systems changed under the poisons effect functions restoration. It is efficient as an antidote in case of intoxications by arsenic and heavy metals salts.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DIMAVAL

PubMed

Sample Use Guides

In Vivo Use Guide
For managing acute and chronic intoxications by arsenic and mercury compounds utnithiol is injected intramuscular or subcutaneous (5 – 10 ml of 5% solution). The treatment should be started as early as possible. In case of intoxications by arsenic compounds injections are every 6 – 8 hours the first day, 2 – 3 injections every 8 – 12 hours the second day, 1 – 2 injections the subsequent days. Children are made intramuscular injections in the doses 1 ml of 5% solution for each 10 kg of the body mass every 6 hours the first day; then 1 – 3 injections a day. In case of intoxications by mercury salts the preparation is injected for not less than 6 days. In case of intoxications by cardiac glicosides it is injected intramuscular or subcutaneous in the dose 5 or 10 ml of the unithiol 5% solution during the first 2 days. Injections are made 3 – 4 times a day. Then it is injected 1 – 2 times a day until the cardiotoxic action stops. In case of hepatocerebral degeneration 5 – 10 ml of the unithiol solution is prescribed for daily or in a day intramuscular injections, the course being 25 – 30 injections with an interval between the courses – 3 – 4 months. In case of diabetic polyneuropathy 5 ml of 5% solution is injected for 10 days. In case of chronic alcoholism the preparation is introduced intramuscular in dose 3 – 5 ml of 5% solution 2 – 3 times a week. For arresting the alcoholic delirium attacks 4 – 5ml of 5% solution is injected intramuscular. 1 ml of the preparation contains 50 mg of unithiol.
Route of Administration: Other
In Vitro Use Guide
When HepG2 cells were co-treated with As3+ (25 uM) and DMPS (Unithiol) (0.02, 0.2, 1.0, or 2.0 mM), cellular arsenic was decreased with the increasing of DMPS concentration from 0.02 mM to 2.0 mM. DMPS at high concentration (>1.0 mM) dramatically decreased the accumulation of arsenic in HepG2 cells. The cellular arsenic was decreased from 5.72% to 0.13% when the cells were treated with 2.0 mM DMPS.
Substance Class Chemical
Record UNII
086L82361J
Record Status Validated (UNII)
Record Version